anti ova primary antibody  (Novus Biologicals)

Journal: Advanced Materials (Deerfield Beach, Fla.)

Article Title: Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

doi: 10.1002/adma.202516661

Figure Lengend Snippet: Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA IgG1 and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.

Article Snippet: The levels of anti‐OVA IgG1 and anti‐OVA IgG2a antibodies were quantified using mouse anti‐OVA IgG1 and mouse anti‐OVA IgG2a antibody assay kits (Chondrex, Inc., Woodinville, WA, USA; Cat# 3013 and 3015) according to the manufacturer's instructions.

Techniques: Expressing